Patents by Inventor William C. Hahn

William C. Hahn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for targeting cancer-specific sequence variations
    Patent number: 11492670
    Abstract: The present invention relates to compositions and methods for targeting cancer-specific DNA sequences, such as copy number amplifications and other types of cancer-specific sequence variations, such as cancer-specific polymorphisms, insertions, or deletions. The present invention provides hereto sequence-specific DNA targeting agents targeting a sequence within the amplified DNA region or a sequence otherwise specific for a cancer cell compared to a non-cancer cell. The invention further relates to methods for treating cancer, comprising administering such sequence-specific DNA targeting agents. The invention further relates to methods for preparing sequence-specific DNA targeting agent, as well as screening methods using the DNA targeting agents.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: November 8, 2022
    Assignees: THE BROAD INSTITUTE INC., DANA-FARBER CANCER INSTITUTE, INC., INSTITUTO CARLOS SLIM DE LA SALUD, A.C.
    Inventors: William C. Hahn, Andrew Aguirre, April Cook, Glenn Cowley, Robin Meyers, David E. Root, Aviad Tsherniak, Barbara Weir, Francisca Vazquez
  • METHODS OF TREATING CANCER HAVING AN ACTIVE WNT/BETA-CATENIN PATHWAY
    Publication number: 20200101070
    Abstract: The present invention provides methods of treating a subject having a Wnt/beta-catenin active cancer by administering to said subject a compound that inhibits the expression or activity of YES1, BIRC5 or BCL2L1, a compound that inhibits YAP1-beta-catenin complex formation, a compound that inhibits YAP1-beta-catenin complex binding to DNA, a compound that inhibits YAP1-beta-catenin-TBX5 complex formation, or any combination thereof. The compound can be, for example, a nucleic acid, a peptide, an antibody or a small molecule. Methods of screening for therapeutic targets for treating cancer are included.
    Type: Application
    Filed: August 26, 2019
    Publication date: April 2, 2020
    Inventors: William C. HAHN, Joseph ROSENBLUH
  • Methods of treating cancer having an active Wnt/?-catenin pathway
    Patent number: 10426774
    Abstract: The present invention provides methods of treating a subject having a Wnt/beta-catenin active cancer by administering to said subject a compound that inhibits the expression or activity of YES1, BIRC5 or BCL2L1, a compound that inhibits YAP1-beta-catenin complex formation, a compound that inhibits YAP1-beta-catenin complex binding to DNA, a compound that inhibits YAP1-beta-catenin-TBX5 complex formation, or any combination thereof. The compound can be, for example, a nucleic acid, a peptide, an antibody or a small molecule. Methods of screening for therapeutic targets for treating cancer are included.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: October 1, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: William C. Hahn, Joseph Rosenbluh
  • METHODS OF IDENTIFYING COMPOUNDS THAT INTERFERE WITH ERG-DRIVEN MISGUIDANCE OF BAF COMPLEXES IN TMPRSS2-ERG DRIVEN PROSTATE CANCERS
    Publication number: 20180328913
    Abstract: The present invention provides methods of screening for compounds that interfere with interaction between ERG. ETV1, ETV4 or ETV5 and mSWI/SNF (BAF) chromatin remodeling complex proteins. Included are methods of screening for compounds that interfere with interaction between ERG, ETV1, ETV4 or ETV5 and BAF155. Methods of treating prostate cancer with compounds that interfere with interaction between ERG, ETV1, ETV4 or ETV5 and mSWI/SNF (BAF) chromatin remodeling complex proteins are also provided.
    Type: Application
    Filed: November 18, 2016
    Publication date: November 15, 2018
    Inventors: Cigall Kadoch, Gabriel Sandoval, William C. Hahn
  • COMPOSITIONS AND METHODS FOR TARGETING CANCER-SPECIFIC SEQUENCE VARIATIONS
    Publication number: 20170114413
    Abstract: The present invention relates to compositions and methods for targeting cancer-specific DNA sequences, such as copy number amplifications and other types of cancer-specific sequence variations, such as cancer-specific polymorphisms, insertions, or deletions. The present invention provides hereto sequence-specific DNA targeting agents targeting a sequence within the amplified DNA region or a sequence otherwise specific for a cancer cell compared to a non-cancer cell. The invention further relates to methods for treating cancer, comprising administering such sequence-specific DNA targeting agents. The invention further relates to methods for preparing sequence-specific DNA targeting agent, as well as screening methods using the DNA targeting agents.
    Type: Application
    Filed: October 20, 2016
    Publication date: April 27, 2017
    Inventors: William C. Hahn, Andrew Aguirre, April Cook, Glenn Cowley, Robin Meyers, David E. Root, Aviad Tsherniak, Barbara Weir, Francisca Vazquez
  • Signatures and determinants associated with cancer and methods of use thereof
    Patent number: 9593377
    Abstract: The present invention provides methods of detecting cancer using biomarkers.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: March 14, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc.
    Inventors: William C. Hahn, Pablo Tamayo, Jesse S. Boehm, Jill P. Mesirov
  • METHODS OF TREATING CANCER HAVING AN ACTIVE WNT/BETA-CATENIN PATHWAY
    Publication number: 20150065518
    Abstract: The present invention provides methods of treating a subject having a Wnt/beta-catenin active cancer by administering to said subject a compound that inhibits the expression or activity of YES1, BIRC5 or BCL2L1, a compound that inhibits YAP1-beta-catenin complex formation, a compound that inhibits YAP1-beta-catenin complex binding to DNA, a compound that inhibits YAP1-beta-catenin-TBX5 complex formation, or any combination thereof. The compound can be, for example, a nucleic acid, a peptide, an antibody or a small molecule. Methods of screening for therapeutic targets for treating cancer are included.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 5, 2015
    Inventors: William C. Hahn, Joseph Rosenbluh
  • Phosphorylated RaIA
    Patent number: 8637260
    Abstract: Antibodies that are specific for human Ra1A that is phosphorylated at one or both of Ser183 and Ser194 are described as various methods such antibodies, including diagnostic methods and screening methods.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: January 28, 2014
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: William C. Hahn, Laura Corral, Anna A. Sablina
  • Signatures and Determinants Associated with Cancer and Methods of Use Thereof
    Publication number: 20130323744
    Abstract: The present invention provides methods of detecting cancer using biomarkers.
    Type: Application
    Filed: November 30, 2011
    Publication date: December 5, 2013
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: William C. Hahn, Pablo Tamayo, Jesse S. Boehm, Jill P. Mesirov
  • Compositions and methods for identifying transforming and tumor suppressor genes
    Patent number: 8178317
    Abstract: Provided herein are nucleic acids, proteins, vectors, cells, kits, devices and methods useful for identifying regulatable proteins that are able to complement components of cellular signaling pathways. Also provided are compositions and methods using these complementing genes directly as markers for cancer diagnosis or prognosis and as targets for anti-neoplastic therapeutics. Further provided are methods for using changes caused by expression of the complementing genes to indirectly identify associated genes to be used as markers for cancer diagnosis or prognosis and as targets for anti-neoplastic therapeutics.
    Type: Grant
    Filed: May 1, 2008
    Date of Patent: May 15, 2012
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Thomas M. Roberts, Jean Zhao, David E. Hill, William C. Hahn, Jesse Boehm
  • Phosphorylated RalA
    Publication number: 20110306057
    Abstract: Antibodies that are specific for human RalA that is phosphorylated at one or both of Ser183 and Ser194 are described as various methods such antibodies, including diagnostic methods and screening methods.
    Type: Application
    Filed: May 16, 2011
    Publication date: December 15, 2011
    Inventors: William C. Hahn, Laura Corral, Anna A. Sablina
  • Molecular Determinants Associated With Prostate Cancer And Methods Of Use Thereof
    Publication number: 20110206689
    Abstract: The present invention provides methods of treating cancer by inhibiting pserine threonine kinase activity and detecting cancer using biomarkers.
    Type: Application
    Filed: January 21, 2011
    Publication date: August 25, 2011
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: William C. Hahn, Atish Choudury, Isil Guney
  • Cancer immunotherapy and diagnosis using universal tumor associated antigens, including hTERT
    Patent number: 7851591
    Abstract: The invention provides methods for conducting cancer immunotherapy and diagnosis using universal tumor associated antigens, such as the telomerase catalytic subunit (hTERT), and methods for identifying and characterizing universal tumor associated antigens.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: December 14, 2010
    Assignee: Dana Farber Cancer Institute, Inc.
    Inventors: Lee M. Nadler, William C. Hahn, Joachim L. Schultze, Robert H. Vonderheide
  • Telomerase RNA Subunit and Methods of Use Thereof
    Publication number: 20090047672
    Abstract: The present invention provides a novel telomere associated RNA (hTERC-2) that mediates the DNA repair function of telomerase.
    Type: Application
    Filed: February 7, 2006
    Publication date: February 19, 2009
    Inventors: William C. Hahn, Richard Possemato, Kenkichi Masutomi
  • Compositions and methods for indentifying transforming and tumor suppressor genes
    Publication number: 20090047675
    Abstract: Provided herein are nucleic acids, proteins, vectors, cells, kits, devices and methods useful for identifying regulatable proteins that are able to complement components of cellular signaling pathways. Also provided are compositions and methods using these complementing genes directly as markers for cancer diagnosis or prognosis and as targets for anti-neoplastic therapeutics. Further provided are methods for using changes caused by expression of the complementing genes to indirectly identify associated genes to be used as markers for cancer diagnosis or prognosis and as targets for anti-neoplastic therapeutics.
    Type: Application
    Filed: May 1, 2008
    Publication date: February 19, 2009
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Thomas M. Roberts, Jean Zhao, David E. Hill, William C. Hahn, Jesse Boehm